摘要
目的评价齐拉西酮治疗精神分裂症的临床疗效和安全性。方法将70例精神分裂症患者随机分为两组各35例，研究组口服齐拉西酮治疗，对照组口服利培酮治疗，观察8w。于治疗前及治疗第2w、4w、8w末采用阳性与阴性症状量表、副反应量表评定临床疗效和不良反应。结果治疗8w末，两组总有效率均为88．57％；治疗第2w末起，两组阳性与阴性症状量表总分均较治疗前有显著性下降（P均〈0．01），并随着治疗的延续呈持续性下降；同期两组间比较均无显著性差异（P均〉0．05）。研究组主要不良反应表现为锥体外系反应、头痛、嗜睡、心电图异常等，未出现体重增加、血糖增高、泌乳素改变等；对照组不良反应主要表现为泌乳素改变、锥体外系反应、体重增加、失眠等。治疗后两组副反应量表评分均无显著性差异（P〉0．05）。结论齐拉西酮与利培酮治疗精神分裂症疗效均显著，不良反应轻微，但齐拉西酮不引起体重增加、血糖增高和泌乳素的改变，适合于肥胖、血糖、血脂异常或女性患者。
Objective To evaluate the efficacy and safety of zirazidone in treating schiazophrenia. Methods 70 schizophrenics were randomly divided into two groups of 35 patients each, research group took orally ziprasidone and control group did risperidone for 8 weeks. Efficacies were assessed with the Positive and Negative Syndrome Scale（PASS） and adverse reactions with the Treatment Emergent Symptom Scale （TESS） before treatment and at the end of the 2nd ,4^th and 8^th week. Results At the end of.the 8^th week, total effective rates of both groups was 88.57% ; since the end of the 2^nd week, the total score of the PANSS of both groups lowered more significantly compared with pretreatment（P〈0.01） and did continously along with time of therapy lasting; there were no significant differences in synchronization intergroup comparisons（P〉0.05）. Adverse reactions were mainly extrapyramidal system response,headache, drowsiness, ECG abnormal etc. and had no weight gain,blood sugar elevation,prolactin change etc. in the research; in the control, adverse reactions were mainly prolactin change, extrapyramidal system response,weight gain, insomnia and so on. After treatment, there was no significant difference in TESS score between the 2 groups（P〉0.05）. Conclusion Both ziprasidone and risperidone have an evident effect and mild adverse reactions in treating schizophrenia,but ziprasidone does＇nt cause weight gain,blood sugar elevation and prolactin change, and is suitable for obesity,abnormal blood sugar and blood fat or female patients.
出处
《临床心身疾病杂志》
CAS
2009年第4期330-331,共2页
Journal of Clinical Psychosomatic Diseases
